Geron Corp. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
66,019.00
151,707.00
114,039.00
115,113.00
94,954.00
163,558
Total Accounts Receivable
564.00
963.00
1,206.00
475.00
436.00
1,168
Other Current Assets
474.00
736.00
647.00
524.00
580.00
1,332
Total Current Assets
67,057.00
153,406.00
115,892.00
116,112.00
95,970.00
166,058
Net Property, Plant & Equipment
92.00
173.00
207.00
183.00
102.00
59
Total Investments and Advances
-
18,932.00
32,661.00
13,954.00
14,241.00
19,167
Other Assets
195.00
-
-
-
-
-
Total Assets
67,344.00
172,511.00
148,760.00
130,249.00
110,313.00
185,284
Accounts Payable
1,397.00
1,033.00
160.00
225.00
503.00
Other Current Liabilities
6,190.00
40,766.00
6,474.00
7,644.00
6,013.00
Total Current Liabilities
7,587.00
41,799.00
6,634.00
7,869.00
6,516.00
Total Liabilities
7,587.00
41,799.00
6,634.00
7,869.00
6,516.00
Common Equity (Total)
59,757.00
130,712.00
142,126.00
122,380.00
103,797.00
Total Shareholders' Equity
59,757.00
130,712.00
142,126.00
122,380.00
103,797.00
Total Equity
59,757.00
130,712.00
142,126.00
122,380.00
103,797.00
Liabilities & Shareholders' Equity
67,344.00
172,511.00
148,760.00
130,249.00
110,313.00

About Geron

View Profile
Address
149 Commonwealth Drive
Menlo Park California 94025
United States
Employees -
Website http://www.geron.com
Updated 07/08/2019
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D.